ERN Survey: How to approach and manage primary mitochondrial diseases (PMDs) in different EU countries. The ERNs survey

This survey is for MDs or residents affiliated to the ERN(s) and practicing in Europe (UK included)

	noide d'all annuelle de la company de la		
*Re	*Required		
1.	Email *		
2.	Data protection. This survey is by invitation only. We will not share or make public information that can link you to individual responses presented in our final report. Do you agree to the above?	*	
	Mark only one oval.		
	Yes		
	◯ No		
	General information		
3.	GENDER *		
	Mark only one oval.		
	MALE		
	FEMALE		
	Non-binary		
	Prefer not to say		
	Other:		

4.	AGE RANGE (YEARS) *		
	Mark only one oval.		
	UNDER 30		
	30-50		
	MORE THAN 50		
5.	Current professional situation: *		
	Mark only one oval.		
	NEUROLOGY RESIDENCY PROGRAMME		
	NEUROLOGIST AFFILIATED TO HOSPITAL\UNIVERSITY		
	NEUROLOGIST IN PRIVATE PRACTICE		
	NEUROPEDIATRICIAN		
	CLINICAL GENETIST		
	OTHER MD SPECIALIST		
	ePAG representative		
	Other:		

Moldova

Monaco
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russia
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Turkey
Ukraine
United Kingdom
Vatican City

7.	ERN(S) YOU ARE AFFILIATED (multiple choices allowed) *
	Tick all that apply.
	ERN NMD
	ERN RND
	EPICare
	MetabERN
	ERN-EYE
	ERN BOND
	ERN CRANIO
	Endo-ERN
	ERKNet
	ERNICA
	ERN LUNG
	ERN Skin
	ERN EURACAN
	ERN EuroBloodNe
	ERN eUROGEN
	ERN GENTURIS
	ERN GUARD-HEART
	ERN ITHACA
	ERN PaedCan
	ERN RARE-LIVER
	ERN ReCONNET
	ERN RITA
	ERN TRANSPLANT-CHILD
	U VASCERN □
	NO ERN AFFILIATION
	General interest in primary mitochondrial diseases (PMDs)
8.	Do you think that PMDs have an important role in clinical practice? *
	Mark only one oval.
	Yes
	◯ No
	Do not know

9.	Are you aware of PMDs? *		
	Mark only one oval.		
	Yes		
	No		
10.	Do you follow patients with PMDs? *		
	Mark only one oval.		
	Yes		
	◯ No		
11.	If you follow patients with PMDs, which one of the listed groups are you familiar with (multiple choices allowed)	*	
	Tick all that apply.		
	Mitochondrial myopathy (including PEO)		
	LHON and ADOA		
	MELAS MERRF		
	Kearns Sayre Syndrome		
	Leigh syndrome		
	Alpers disease		
	Multisystem PMDs		
	Others NONE		
12.	Do you think that a family history, including matrilinear inheritance, is usually collected?	*	
	Mark only one oval.		
	Yes		
	◯ No		
	I do not know		

13.	Do you think that family history is an important finding in the diagnostic flowchart?	*
	Mark only one oval.	
	Yes	
	No	
	Maybe	
14.	When you have a patient with a possible PMD, what is your attitude (multiple choices allowed):	*
	Tick all that apply.	
	you send the patient to a subspecialist in the field	
	you ask directly the appropriate gene testing you prescribe specific drugs and manage the follow up	
	PMDs codes	
15.	Are you happy with the ICD-10 codes for classifying PMDs discharged from your HCP?	*
	Mark only one oval.	
	Yes	
	◯ No	
	I do not know	
16.	Do you think PMDs deserve specific ICD codes for reimbursement reasons or for better attention and tailored healthcare for these patients	*
	Mark only one oval.	
	Yes	
	◯ No	
	I do not know	

Analysis for PMDs diagnosis

17.	Muscle biopsy available at your HCP *		
	Mark only one oval.		
	Yes No I do not know		
18.	Single gene analysis available at your HCP *		
	Mark only one oval.		
	YES NO I do not know		
19.	Single Gene analysis RESPONSE waiting time		
	Mark only one oval. < 3 months 3-6 months > 6 months I do not know 		
20.	NGS Panels for PMDs available at your HCP * Mark only one oval. Yes		
	No I do not know		

21.	NGS Panels for PMDs RESPONSE waiting time
	Mark only one oval.
	< 3 months
	3-6 months
	> 6 months
	I do not know
22.	Exome available at your HCP *
	Mark only one oval.
	Yes
	No
	for scientific purpose only
	I do not know
23.	Exome for PMDs RESPONSE waiting time *
	Mark only one oval.
	<3 months
	3-6 months
	> 6 months
	I do not know
24.	Whole Genome (WGS) available at your HCP *
	Mark only one oval.
	Yes
	No
	for scientific purpose only
	I do not know

	Mark only one oval.		
	<3 months 3-6 months > 6 months I do not know		
	Presymptomatic diagnosis	If your answer to the first question is No/I do not know, please jump to next section	
26.	IS THE PRESYMPTOR	MATIC DIAGNOSIS SERVICE AVAILABLE IN YOUR	*
	Mark only one oval.		
	Yes No I do not know		
27.	COUNSELING CONSU	MATIC DIAGNOSIS PRECEDED BY A MEDICAL GENETIC JLTATION?	
	Mark only one oval.		
	Yes		
	No I do not know		
	1 do not know		

25. WGS for PMDs RESPONSE waiting time

	GENETIC TESTING IN PRESYMPTOMATIC SUBJECTS?		
	Mark only one oval.		
	Yes No I do not know	N	
29.	IS THE PRESYMP (<18-YRS)?	TOMATIC DIAGNOSIS SCREENING PERFORMED IN MINORS	
	Mark only one ova	al.	
	yes no ONLY IF THE	RE IS A TREATMENT ABLE TO CHANGE THE NATURAL HISTORY	
	I do not know		
	Prenatal diagnosis	If your answer to the first question is No/I do not know, please jump to next section	
30.	IS THE PRENATA Mark only one ova Yes No I do not know		

28. IS THE SPECIALIST WITH EXPERTISE IN PMDs ALLOWED TO PRESCRIBE

	COUNSELING CONSULTATION?
	Mark only one oval.
	Yes No I do not know
32.	Which specialist is allowed to prescribe genetics test for prenatal diagnosis in *your country (multiple choices allowed)
	Tick all that apply. Medical Genetist Gynecologist Pediatrician expert in PMDs Neurologist expert in PMDs Other MDs I do not know
	Preimplantation genetic diagnosis (PGD)
33.	IS PGD AVAILABLE IN YOUR COUNTRY? *
	Mark only one oval.
	Yes No I do not know
34.	Is there a law of the management of PGD in your country? *
	Mark only one oval.
	Yes No I do not know

31. IS THE PRENATAL DIAGNOSIS PRECEDED BY A MEDICAL GENETIC

35.	IS PGD PRECEDED BY A MEDICAL GENETIC COUNSELING CONSULTATION? *
	Mark only one oval.
	Yes No
	I do not know
	Management of PMDs
36.	Do you prescribe the mitochondrial cocktail to your PMD patients *
	Mark only one oval.
	Yes
	No
	I do not know
37.	if you prescribe the mitochondrial cocktail, what do you usually consider (multiple choices allowed)
	Tick all that apply.
	Coenzime Q10 and analogues
	Riboflavine
	carnitine
	lipoic acid
	vitamin E
	vitamin C
	Other
	None

38.	Is the mitochondrial cocktail reimbursed by the health system of your Country? *
	Mark only one oval.
	Yes
	No
	I do not know
	EDUCATION ON MITOCHONDRIAL DISEASES
39.	Is there a need for education and training in PMDs? *
	Mark only one oval.
	Yes
	No
	I do not know
40	In there a need for adjunction and training in the regidency programme in DMDs *
40.	Is there a need for education and training in the residency programms in PMDs *
	Mark only one oval.
	Yes
	No
	I do not know
41.	Do you think ERNs must provide more education on PMDs through different *initiatives
	Mark only one oval.
	Yes
	No
	I do not know

This content is neither created nor endorsed by Google.

Google Forms